title: Experience with portal-enteric pancreas transplant at the University of Tennessee-Memphis.
abstract: The UT-Memphis Group has made a number of important contributions to the field of PTX including: 1. Pioneering studies on the effects of PTX on autonomic neuropathy;(15, 16) 2. Comprehensive reports dealing with quality of life after PTX;(17, 18, 38) 3. Seminal studies on the metabolic effects of PTX with portal venous delivery of insulin;(33,34) 4. Refining and perfecting a novel technique of PTX with portal venous drainage of insulin and primary enteric drainage of the exocrine secretions;(2,6,11,19) 5. Describing a percutaneous technique of pancreas biopsy;(20) and 6. Pioneering the use of glucose tolerance for rejection surveillance.(24) The P-E technique has the potential to become the standard of care in the near future because it is more physiologic, normalizes carbohydrate and lipid metabolism, and minimizes complications attributed to the transplant procedure. In addition, we have been actively involved in studying new immunosuppressive regimens in order to improve and simplify the care of the PTX recipient. We believe that PTX will remain an important option in the treatment of IDDM until other strategies are developed that can provide equal glycemic control with less or no immunosuppression or less overall morbidity.
authors.affiliation: Department of Surgery (Division of Transplantation), University of Tennessee-Memphis, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Stratta
authors.forename: A O
authors.initials: AO
authors.lastname: Gaber
authors.forename: M H
authors.initials: MH
authors.lastname: Shokouh-Amiri
authors.forename: M F
authors.initials: MF
authors.lastname: Egidi
authors.forename: H P
authors.initials: HP
authors.lastname: Grewal
authors.forename: K S
authors.initials: KS
authors.lastname: Reddy
authors.forename: D K
authors.initials: DK
authors.lastname: Hathaway
authors.forename: R P
authors.initials: RP
authors.lastname: Winsett
authors.forename: R R
authors.initials: RR
authors.lastname: Alloway
authors.forename: L W
authors.initials: LW
authors.lastname: Gaber
authors.forename: L G
authors.initials: LG
authors.lastname: Britt
mesh_terms: D000328:Adult; D001158:Arteries / Q000601:surgery; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006650:Histocompatibility Testing; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D017538:Mesenteric Artery, Superior / Q000601:surgery; D016035:Pancreas Transplantation / Q000379:methods* / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D011169:Portal Vein / Q000601:surgery; D012189:Retrospective Studies; D013154:Spleen / Q000098:blood supply; D015996:Survival Rate; D013714:Tennessee
chemical_list: D007166:Immunosuppressive Agents